Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Immunovia AB (1YR) Stock Price & Analysis

1YR Stock Chart & Stats

€0.01€0.00(0.00%)
At close: 2:00 AM GMT+2
€0.02€0.04€0.062 Sep6 Oct
Day’s Range
EUR 0.01 - EUR 0.01
52-Week Range
EUR 0.01 - EUR 0.03
Previous Close
EUR 0.01
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 3.07M
Enterprise Value
EUR 99.54M
Total Cash (Recent Filing)
EUR 34.90M
Total Debt (Recent Filing)
EUR 3.27M
Price to Earnings (P/E)
―
Beta
109.59
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

PancreaSure Adoption

Adoption across 36 surveillance programs, with one-third ordering consistently, indicates growing clinical acceptance and repeat utilization. Expansion into additional physician groups can broaden the addressable customer base and create a more durable commercial foundation for PancreaSure.

Revenue Growth

Rapid year-over-year sales growth and increased test volumes show that commercialization is beginning to translate into revenue. Continued expansion from a very small base could improve operating leverage over time if adoption and reimbursement progress remain established.

Low Financial Leverage

Low debt reduces the burden of interest and mandatory repayments, preserving financial flexibility compared with a highly leveraged diagnostics company. This gives management more room to direct future financing toward commercialization, clinical studies, and laboratory operations.

Bears Say

Persistent Losses And Cash Burn

Large recurring losses and deeply negative cash generation show that the current revenue base does not support the operating cost structure. Continued cash outflows can erode equity and require repeated external financing unless commercialization scales materially and margins improve.

Dilutive Funding Dependence

Reliance on a highly dilutive rights issue indicates that internal cash generation is not yet sufficient to fund operations through 2027. Further equity financing can materially reduce existing shareholders' ownership and may remain necessary if losses persist or planned proceeds prove insufficient.

Reimbursement Uncertainty

Uncertain Medicare timing and limited commercial payment data make future realized pricing and test volumes difficult to assess. Without broader reimbursement support, clinical adoption may not convert into predictable revenue quickly enough to support the company's cost base.

Immunovia AB News

1YR FAQ

What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is €3.07M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s next earnings report is estimated for Nov 02, 2026 (not yet confirmed), which is 1 day ago.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.004 by €0.001.
Is Immunovia AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.00.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in DE:1YR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology